1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Pulmonary 5-HT
2B receptor expression in fibrotic interstitial lung diseases.
(
- Contribution to journal › Article
- 2022
-
Mark
Ciliated (FOXJ1+) Cells Display Reduced Ferritin Light Chain in the Airways of Idiopathic Pulmonary Fibrosis Patients
(
- Contribution to journal › Article
- 2021
-
Mark
Pathological insight into 5-ht2b receptor activation in fibrosing interstitial lung diseases
(
- Contribution to journal › Scientific review
-
Mark
Distal lung microenvironment triggers release of mediators recognized as potential systemic biomarkers for idiopathic pulmonary fibrosis
(
- Contribution to journal › Article
- 2020
-
Mark
Silver nanoparticles alter cell viability ex vivo and in vitro and induce proinflammatory effects in human lung fibroblasts
(
- Contribution to journal › Article
-
Mark
Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity : Common molecular pathways in Covid-19 and pulmonary fibrosis
(
- Contribution to journal › Article
- 2019
-
Mark
Tissue remodelling in pulmonary fibrosis linked to 5-HT2 receptor activation
(
- Thesis › Doctoral thesis (compilation)
- 2018
-
Mark
Effects of 5-Hydroxytryptamine Class 2 Receptor Antagonists on Bronchoconstriction and Pulmonary Remodeling Processes
(
- Contribution to journal › Article
-
Mark
Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT2B receptor antagonists in vitro - A potential pathway affecting proliferation
(
- Contribution to journal › Article
- 2016
-
Mark
5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo
(
- Contribution to journal › Article